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Abstract. 
 
Coat protein I (COPI) transport vesicles can 
be tethered to Golgi membranes by a complex of ﬁ-
brous, coiled-coil proteins comprising p115, Giantin 
and GM130. p115 has been postulated to act as a 
bridge, linking Giantin on the vesicle to GM130 on the 
Golgi membrane. Here we show that the acidic COOH 
terminus of p115 mediates binding to both GM130 and 
Giantin as well as linking the two together. Phosphory-
lation of serine 941 within this acidic domain enhances 
the binding as well as the link between them. Phosphor-
ylation is mediated by casein kinase II (CKII) or a 
CKII-like kinase. Surprisingly, the highly conserved 
 
NH
 
2
 
-terminal head domain of p115 is not required for 
 
the NSF (
 
N
 
-ethylmaleimide–sensitive fusion protein)–
catalyzed reassembly of cisternae from mitotic Golgi 
fragments in a cell-free system. However, the ability of 
p115 to link GM130 to Giantin and the phosphoryla-
tion of p115 at serine 941 are required for NSF-cata-
lyzed cisternal regrowth. p115 phosphorylation may be 
required for the transition from COPI vesicle tethering 
to COPI vesicle docking, an event that involves the for-
mation of t-SNARE (trans–soluble NSF attachment 
protein [SNAP] receptor) complexes.
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Introduction
 
The Golgins comprise a family of coiled-coil proteins that
localize to the Golgi apparatus and were first identified us-
ing the sera from patients with autoimmune diseases such
as Sjögren’s syndrome (Chan and Fritzler, 1998). Their se-
quence predicts long, rod-like proteins, often with one or
more flexible hinges. The NH
 
2
 
- and COOH-terminal ends
interact either directly or indirectly with membranes and
increasing evidence suggests that they act as tethering pro-
teins, linking transport vesicles with cisternae and cister-
nae with each other (Linstedt et al., 1995; Nakamura et al.,
1995, 1997; Sapperstein et al., 1996; Barr et al., 1998; Barr,
1999; Cao et al., 1998; Sönnichsen et al., 1998; Kim et al.,
1999; Shorter and Warren, 1999). They are thought, there-
fore, to contribute both to the structure of the Golgi appa-
ratus and the movement of transport vesicles through it.
The best characterized Golgins are GM130 and Giantin
(Linstedt and Hauri, 1993; Nakamura et al., 1995). GM130
is mostly present on cis-Golgi membranes and is anchored
at the extreme COOH terminus to GRASP65 (Nakamura
et al., 1995; Barr et al., 1998), one of at least two GRASPs
implicated in the stacking of Golgi cisternae (Barr et al.,
1997; Shorter et al., 1999). Giantin is a type II Golgi mem-
brane protein (Linstedt and Hauri, 1993) and is present
throughout the Golgi apparatus (Seelig et al., 1994), but
appears to be most active when incorporated into COPI
transport vesicles (Sönnichsen et al., 1998).
 
The NH
 
2
 
-terminal domains of both proteins interact with
another coiled-coil protein, p115 (Nakamura et al., 1997;
Lesa et al., 2000). This homodimeric protein has a globular
head domain, a coiled-coil tail and a short acidic region at the
COOH-terminal end (Waters et al., 1992; Sapperstein et al.,
1995). This acidic region has been implicated in binding to
both GM130 (Nelson et al., 1998) and Giantin (Linstedt et
al., 2000). p115 is involved in several transport steps including
ER to Golgi (Lupashin et al., 1996; Sapperstein et al., 1996;
Barlowe, 1997; Alvarez et al., 1999) and transport within the
Golgi stack itself (Waters et al., 1992; Seemann et al., 2000).
It mediates the tethering of coat protein I (COPI)
 
1
 
 vesicles
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with Golgi membranes through its interaction with
GM130 and Giantin (Sönnichsen et al., 1998; Shorter and
Warren, 1999). It is thought to act as a bridge, linking
GM130 on the Golgi with Giantin on the vesicle (Sönnich-
sen et al., 1998).
Tethering occurs before SNARE pairing (Pfeffer, 1999).
The interaction of a v-SNARE on the vesicle with the cog-
nate t-SNARE on the membrane leads to membrane fu-
sion (Rothman, 1994). The yeast counterpart of p115,
Uso1p, tethers coat protein II (COPII) transport vesicles
to Golgi membranes (Cao et al., 1998). This tethering step
occurs before SNARE pairing and is regulated by the
small GTPase, Ypt1p, which interacts genetically with
Uso1p (Sapperstein et al., 1996; Cao et al., 1998). Tether-
ing also requires the protein complex, TRAPP (Sacher et
al., 1998) and the Sec34/35p complex (VanRheenen et al.,
1998, 1999; Kim et al., 1999). The yeast homologues of
GM130 and Giantin have not yet been identified, but
Sec34p interacts genetically with the RUD3/GRP1, a gene
encoding a Golgin-160–related protein (Fritzler et al.,
1993; Kim et al., 1999; VanRheenen et al., 1999). Other
Golgi tethers may include Golgin-230/245/256 and Golgin-
97 which have recently been shown to interact with Rab6
(Barr, 1999), another small GTPase implicated in regulat-
ing the directionality of membrane traffic and membrane
dynamics within the Golgi stack (Martinez et al., 1994;
Echard et al., 1998).
Tethers that bring a vesicle to a membrane with which it
fuses must subsequently be dismantled to permit further
rounds of tethering. The mechanism is unclear but one
clue comes from recent work showing that p115 is specifi-
cally phosphorylated on a serine within the acidic tail re-
gion (Sohda et al., 1998). Phosphorylation correlates with
release of p115 into the cytosol. Here we have investigated
the role played by this serine in the functioning of p115. To
do this we have used a system that mimics many aspects of
Golgi reassembly at the end of mitosis (Rabouille et al.,
1995; Shorter and Warren, 1999). Golgi disassembly dur-
ing mitosis is thought to occur as part of the inheritance
process (Shima et al., 1997). Mitotic Golgi fragments
(MGF) prepared in vitro, will reassemble into Golgi cister-
nae using either one of two ATPases, NSF or p97
(Rabouille et al., 1995). The NSF pathway requires p115 as
one of the components added to the incubation (Rabouille
et al., 1995). Its interaction with GM130 and Giantin is es-
sential both to reconstitute cisternae and to stack them
(Shorter and Warren 1999). Using this system we have
identified a crucial role for the acidic tail serine and have
characterized the kinase which phosphorylates it.
 
Materials and Methods
 
Materials
 
All reagents were analytical grade or higher and purchased from Sigma-
Aldrich, Boehringer, or BDH Chemicals Ltd., unless otherwise stated.
 
Antibodies
 
Antibodies were as follows: 4H1 mouse mAb against p115 (termed mAb
115-1; Waters et al., 1992); mouse mAb against RGS-His (QIAGEN);
NN5-1 rabbit polyclonal and 2C10 mouse mAb against GM130 (Naka-
mura et al., 1997); rabbit polyclonal (Dr. Manfred Renz, Institute of Im-
munology and Molecular Genetics, Karlsruhe, Germany) and mouse
 
mAb (Dr. Hans-Peter Hauri, Department of Pharmacology/Neurobiol-
ogy, Biozentrum, University of Basel, Switzerland) against Giantin;
mouse mAbs against human CKII-
 
a 
 
subunit and -
 
b
 
 subunit (Calbiochem-
Novabiochem).
 
Molecular Cloning
 
Site directed mutagenesis was used to construct vectors for expression of
portions of bovine p115 (see Fig. 1). HTA represents the full-length un-
mutagenized construct. The HT construct was generated by changing the
codon for D906 to a stop codon (TAG) and the H construct was made by
changing the codon for V652 to a stop codon (TAG). The TA construct
was generated as follows. First the R5 and G6 codons (AAG-CTT) were
changed to a StuI restriction (site AGG-CCT). In a second round of mu-
tagenesis the I651 and V652 codons (ATT-GTG) were changed to a PmlI
restriction site (CAC-GTG). The plasmid was then digested with StuI and
PmlI and ligated. The resulting TA construct encodes the first five amino
acid residues of p115 fused with residues V652 to the COOH terminus.
All constructs were subsequently cloned into pBluescriptII. TA constructs
were mutagenized changing codon S941 (AGC) to either alanine (GCC)
(TA [S941A]), or aspartic acid (GAC) (TA[S941D]).
GM130 pBluescriptII constructs (Nakamura et al., 1997) were used for
in vitro transcription-translation reactions in the presence of 
 
35
 
S-methio-
nine using T3 polymerase according to the manufacturer’s instructions
(Promega). An amount corresponding to 
 
z
 
10 ng of the relevant in vitro
translated protein (10 
 
m
 
l reticulolysate containing translation product)
was used for coimmunoprecipitation reactions (see below).
 
Protein Expression and Purification
 
His
 
6
 
-TA was generated by subcloning in the expression vector pQE9
(QIAGEN). It was expressed in 
 
E
 
.
 
 coli
 
 XL1-blue, and purified according
to the manufacturer’s instructions.
TA, TA (S941A), and TA (S941D) were further fractionated by Super-
ose-6 (Amersham Pharmacia Biotech) gel-filtration in 20 mM Hepes/
KOH, pH 7.3, 200 mM KCl, 10 mM MgCl
 
2
 
, 1 mM DTT, and 5% (wt/vol)
glycerol. Trypsin digestion of TA mutants was performed with trypsin
concentrations ranging from 0 to 10 
 
m
 
g/ml. Purification of rat liver p115
was performed according to Levine et al., 1996.
 
Synthetic Peptides
 
p115 peptides: the 75mer (LQNEKNKLEVDITDSKKEQDDLLVL-
LADQDQKIFSLKNKLKELGHPVEEEDELES*GDQDDEDDED-
EDDGKEQGHI) and 26mer (EDELES*GDQDDEDDEDEDDG-
KEQGHI), were both synthesized either with or without phosphorylation
of the serine marked (*) and with an NH
 
2
 
-terminal biotin-tag. The NH
 
2
 
-
terminal GM130 peptide is characterized in Nakamura et al. (1997). The
standard CKII peptide substrate (RRRDDDS*DDDDD) was synthe-
sized with or without a phosphorylation of the marked serine (*). All pep-
tides were provided by the Peptide Synthesis Laboratory at Imperial Can-
cer Research Fund (ICRF).
 
Overlays
 
Overlays were performed using 0.1 mg/ml biotin-75mer peptide (Naka-
mura et al., 1997).
 
Light Scattering
 
Light scattering of TA, TA (S941A), TA (S941D), and 75mer peptide was
performed in 20 mM Hepes/KOH, pH 7.3, 50 mM KCl, 10 mM MgCl
 
2
 
,
and 0.1 mM DTT using a miniDAWN machine following the manufac-
turer’s instructions. Molecular weight was calculated using ASTRA soft-
ware (Wyatt Technology Corporation).
 
Golgi Membrane Extracts
 
Purified rat liver Golgi membranes (RLG; Hui et al., 1998) were washed
with 1 M KCl in sucrose buffer (0.2 M sucrose, 50 mM potassium phos-
phate, pH 6.7, and 5 mM MgCl
 
2
 
) with added protease inhibitors (Naka-
mura et al., 1995) or 0.1 M sodium carbonate, pH 11. Membranes were re-
washed with sucrose buffer and pellets extracted with 20 mM Hepes/
KOH, pH 7.3, 200 mM KCl, 1 mM DTT, 1 mM EDTA, 1% (wt/vol) Tri-
ton X-100, 10 mM MgCl
 
2
 
, and protease inhibitors for 1 h on ice. Extracts
were then diluted with one vol of 20 mM Hepes/KOH, pH 7.3, to yield 
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Triton X-100 buffer (20 mM Hepes/KOH, pH 7.3, 100 mM KCl, 0.5 mM
DTT, 0.5 mM EDTA, 0.5% [wt/vol] Triton X-100, and 5 mM MgCl
 
2
 
), and
clarified by centrifugation at 20,000 
 
g
 
 for 10 min at 4
 
8
 
C. 1 mg starting RLG
was extracted and diluted into 1 ml Triton X-100 buffer.
 
Generation of Peptide and TA Beads
 
NH
 
2
 
-terminally biotinylated synthetic peptides were coupled to neutravi-
din beads (Pierce) in Triton X-100 buffer (Nakamura et al., 1997). His
 
6
 
-
TAs were bound to magnetic Ni-NTA agarose beads (QIAGEN) in 20
mM Hepes/KOH, pH 7.3, 200 mM KCl, 10 mM MgCl
 
2
 
, 1 mM DTT, and
5% glycerol for 2 h at 4
 
8
 
C. Beads were subsequently washed into Triton
X-100 buffer. Binding of proteins from salt-washed RLG extracts to pep-
tide/TA beads was carried out by incubation in Triton X-100 buffer for 1 h
at 4
 
8
 
C (Nakamura et al., 1997).
 
Immunoprecipitations
 
These were carried out using extracts of RLG (100 
 
m
 
g/reaction), which
had been washed in either 1 M KCl or 0.1 M carbonate, pH 11. In some
experiments, in vitro–translated and 
 
35
 
S-labeled proteins (
 
z
 
10 ng p115
[HTA, HT, H, TA], GM130, or 
 
D
 
-N-GM130) were preincubated with the
membrane extracts. In others, purified rat liver p115, TA, TA (S941A),
TA (S941D) and p115 -26mer and -75mer peptides were added. Preincu-
bations were performed in Triton X-100 buffer for 1 h at 4
 
8
 
C. In experi-
ments involving CKII (0.2 
 
m
 
units, recombinant human CKII; Calbiochem-
Novabiochem), reactions were subsequently incubated at 30
 
8
 
C for 10 min
in the presence of 10 
 
m
 
M GTP and 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]GTP. Reactions were in-
cubated with polyclonal anti-Giantin, anti-p115, or anti-GM130 antibod-
ies (3 
 
m
 
l of the appropriate antiserum and 20 
 
m
 
l of packed protein A
beads; Amersham Pharmacia Biotech) for 2 h at 4
 
8
 
C. Beads were washed
with Triton X-100 buffer, and proteins eluted in SDS sample buffer. Sam-
ples were fractionated by SDS-PAGE, immunoprecipitated and coimmu-
noprecipitated proteins were detected by Western blotting using mAbs, or
in experiments where 
 
35
 
S-labeled proteins were added by exposure to a
PhosphorImager. PhosphorImager quantitation was carried out using Im-
agequant. In all experiments, signals were corrected for immunoprecipita-
tion efficiencies by detecting the protein the antibody was directed against
using mAbs. Western blot signals were quantitated using NIH-image.
 
In Vitro Protein Phosphorylation
 
CKII-, RLG- and MGF-mediated phosphorylation of p115 was carried
out by incubation of 0.2 
 
m
 
units of recombinant human CKII (Calbiochem-
Novabiochem), 10 
 
m
 
g RLG, or 10 
 
m
 
g MGF with either p115, TA, or TA
(S941A) in the presence of either 10 
 
m
 
M GTP, and 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]GTP, or
10 
 
m
 
M ATP and 5 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]ATP (unless otherwise stated) in phosphory-
lation buffer (20 mM Hepes/KOH, pH 7.3, 50 mM KCl, 10 mM MgCl
 
2
 
, 0.1
mM DTT, and 0.2 M sucrose) with added protease inhibitors (Nakamura
et al., 1995). Reactions were carried out for 10 min at 30
 
8
 
C unless other-
wise stated. In some experiments reactions contained a 100
 
3
 
 molar excess
(over the final p115 concentration in the reaction) of either the phosphor-
ylated or nonphosphorylated CKII standard substrate. In other experi-
ments reactions contained either staurosporine, DRB, chrysin, rosco-
vitine, KT5720, H-89, or calphostin C at the concentrations indicated in
the text or figure legends (all kinase inhibitors were from Calbiochem-
Novabiochem, except chrysin, which was from Sigma-Aldrich); or, 1 
 
m
 
l
anti–CKII-
 
a
 
 or 1 
 
m
 
l anti–CKII-
 
b
 
 antibodies. CKII-mediated phosphoryla-
tion reactions were terminated by addition of SDS-PAGE sample buffer.
RLG-mediated phosphorylation reactions were terminated by addition of
KCl to a final concentration of 1 M on ice, releasing p115/TA from RLG.
The RLG were removed by centrifugation. SDS-PAGE sample buffer was
added directly to resulting samples containing p115. Samples containing
TA were incubated with Ni beads to recover His-tagged proteins. Phos-
phorylated p115/TA proteins were visualized by Coomassie staining fol-
lowed by exposure to a PhosphorImager.
RLG-mediated phosphorylation of a standard CKII peptide substrate
was carried out in the presence of 35 
 
m
 
M GTP and 10 
 
m
 
Ci 
 
g
 
-[
 
32
 
P]GTP at
30
 
8
 
C. Reactions were dotted onto phosphocellulose filters, washed in 100
mM phosphoric acid followed by 100% ethanol, dried, and phosphoryla-
tion levels quantitated using a scintillation counter.
 
Golgi Reassembly Reactions
 
MGF were generated as described (Shorter and Warren, 1999), and were
incubated at 0.75–1 mg/ml for 60 min at 37
 
8
 
C with NSF (100 ng/
 
m
 
l),
 
a
 
-SNAP (25 ng/
 
m
 
l), 
 
g
 
-SNAP (25 ng/
 
m
 
l), an ATP regeneration system, and
either 0–260 nM rat liver p115, TA (or TA mutants), 75mer, or 26mer.
The final reaction volume was 20 
 
m
 
l. In some experiments, the MGF were
preincubated for 15 min on ice before reassembly with a 100
 
3
 
 molar ex-
cess of CKII substrate or the same substrate phosphorylated on the serine
residue. In other experiments, reassembly was conducted in the presence
of either 100 
 
m
 
M staurosporine, DRB, chrysin, or roscovitine, or 1 
 
m
 
l anti–
CKII-
 
a
 
 or 1 
 
m
 
l anti–CKII-
 
b
 
 antibodies. Reactions were fixed and pro-
cessed for EM, and the amount of cisternal regrowth determined
(Rabouille et al., 1995).
 
Results
 
p115 Binds to GM130 and Giantin via Its
COOH-terminal Acidic Domain
 
To understand how p115 acts to tether membranes and
vesicles we investigated the role played by phosphoryla-
tion of p115. First, however, we tested whether the
COOH-terminal region of p115 that contains the serine
known to be phosphorylated in vivo (Sohda et al., 1998)
binds directly to GM130 and Giantin.
Truncated forms of p115 (Fig. 1) were tested for their
ability to bind to GM130 and Giantin. We generated DNA
constructs encoding full-length p115 (HTA) and p115
lacking either the acidic domain (HT), the coiled-coil tail
and acidic domain (H), or the globular head domain (TA).
Serine 941, the bovine equivalent of the human serine 942
that is phosphorylated in p115 in vivo, is located within the
acidic domain (A; Sohda et al., 1998). The DNA was tran-
scribed and translated in vitro in the presence of 
 
35
 
S-
methionine. The translated proteins were mixed with de-
tergent extracts of rat liver Golgi (RLG) membranes
containing both Giantin and GM130, but from which
 
.
 
95% of the endogenous p115 had been removed by
washing with 1 M KCl. Giantin or GM130 were then im-
munoprecipitated and coimmunoprecipitation of the dif-
ferent p115 forms monitored (Fig. 2 A). The same p115
binding pattern was obtained for both GM130 and Gian-
Figure 1. Schematic illustration of p115 constructs. p115 con-
structs were generated using the bovine cDNA. The full-length
p115 sequence (HTA) encodes a globular head domain (boxed in
white), a coiled-coil tail domain (boxed in light gray) and a short
acidic region (boxed in dark gray). DNA encoding truncated
forms of p115 was as follows: HT encodes the head region and
most of the tail region (amino acids 1–905). H encodes the head
domain alone (amino acids 1–651), while TA encodes the tail and
acidic domains (amino acids 652–961). Two COOH-terminal
peptides were also synthesized: A 75mer comprising a short
stretch of coiled coil sequence and the acidic domain (amino ac-
ids 887–961), and a 26mer comprising the acidic domain alone
(amino acids 936–961). Serine 941 in the bovine sequence
(boxed) is equivalent to Serine 942 in the human sequence, which
is known to be phosphorylated in vivo (Sohda et al., 1998). 
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tin, and showed that only those forms of p115 containing
the acidic domain (A) coimmunoprecipitated. HTA and
TA bound very well, whereas HT and H only gave signals
similar to those obtained with nonimmune sera (data not
shown). Furthermore, TA bound about twice as well as
HTA suggesting that the globular head domain may regu-
late the binding.
A direct role for the acidic domain of p115 in binding to
GM130 and Giantin was obtained using two COOH-ter-
minal peptides containing serine 941 (see Fig. 1): a 75mer
representing a short stretch of the coiled coil region in ad-
dition to the acidic region; and a 26mer representing only
the acidic region of p115. The peptides were NH
 
2
 
-termi-
nally biotinylated and coupled to neutravidin beads. The
beads were then incubated with detergent extracts of salt
washed RLG and binding of GM130 and Giantin moni-
tored. Both peptides selectively extracted GM130 and Gi-
antin when compared with mock beads (Fig. 2 B).
To test whether the acidic domain of p115 could bind
Giantin and GM130 separately we used sources of GM130
and Giantin that contained only one of the two proteins.
 
35
 
S-labeled GM130 generated by in vitro transcription and
translation was used as a source of GM130. 75mer and
26mer (data not shown) peptide beads, but not mock
beads, bound in vitro translated GM130 (Fig. 2 C). As a
control, an NH
 
2
 
-terminal truncated form of GM130 (
 
D
 
N-
GM130) lacking the p115 binding site (Nakamura et al.,
1997) was used. Neither mock nor 75mer peptide beads
bound this form of GM130 (Fig. 2 C).
To generate a Giantin source containing no GM130,
RLG were washed in carbonate buffer, pH 11, which re-
moves more than 98% of the GM130 as well as the p115
(Nakamura et al., 1995). The membranes were then ex-
tracted in Triton X-100 buffer and incubated with either
mock beads or 75mer peptide beads. The 75mer beads, but
not the mock beads, bound Giantin (Fig. 2 D).
Further evidence for a direct interaction of the acidic
domain of p115 with Giantin and GM130 came from over-
lays using the biotin-75mer peptide (Fig. 2 E). RLG pro-
teins were fractionated by SDS-PAGE, transferred to ni-
trocellulose, incubated with biotin-75mer and the bound
peptide visualized using streptavidin-HRP and ECL. The
75mer bound to Giantin and GM130, but not to p115. Sim-
ilar results were obtained using the 26mer peptide (data
not shown). We conclude that Giantin and GM130 can
bind directly and independently to the acidic domain of
p115.
 
The Acidic Domain of p115 Is Not Sufficient for 
Reassembly of Golgi Cisternae
 
The forms of p115 that could bind Giantin and GM130
were next tested for their ability to regrow cisternae from
Figure 2. The COOH-terminal acidic region
of p115 binds to GM130 and Giantin. (A)
Coupled in vitro transcription-translation re-
actions were performed using plasmids en-
coding HTA, HT, H, and TA. Each translate
was mixed with salt washed RLG extracted in
Triton X-100 buffer. Either Giantin or
GM130 was immunoprecipitated using poly-
clonal antibodies and coimmunoprecipitation
of the different forms of p115 analyzed by
SDS-PAGE followed by PhosphorImager vi-
sualization and quantitation. Values represent
means  6  SEM (n 5 3–5). (B) Salt washed
RLG (200 mg) were solubilized in Triton
X-100 buffer and incubated with either mock,
26mer, or 75mer beads. Proteins bound were
separated by SDS-PAGE and visualized by
Coomassie staining or Western blotting using
antibodies to Giantin and GM130. (C) 35S-
GM130 (lane 1) and 35S–DN-GM130 (lane 2)
were generated by transcription and transla-
tion in vitro. After incubation with either
mock beads (GM130: lane 3, DN-GM130: lane
4) or 75mer peptide beads (GM130: lane 5,
DN-GM130: lane 6) the bound proteins were
visualized by SDS-PAGE followed by expo-
sure to a PhosphorImager (lanes 3–6) as was
10% of the in vitro translated proteins added
to the beads (lanes 1 and 2). (D) RLG mem-
branes (200 mg) were washed with carbonate
buffer to remove p115 and GM130 before ex-
traction in Triton X-100 buffer. Extracts were
incubated with mock or 75mer peptide beads and bound proteins were separated by SDS-PAGE and visualized by Western blotting us-
ing anti–Giantin antibodies. (E) RLG proteins (10 mg) were separated by SDS-PAGE and transferred to nitrocellulose. Blots were ei-
ther overlaid with biotin 75mer followed by streptavidin-HRP and ECL to detect the bound peptide (left) or probed with antibodies di-
rected against Giantin (middle) or GM130 and p115 (right). (*Giantin fragment; r GM130 fragments.) 
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MGF. p115 lacking the head domain (TA) was generated
in 
 
E
 
.
 
 coli
 
 and purified using an NH
 
2
 
-terminal His
 
6
 
tag. We
compared the ability of TA and the short peptides to stim-
ulate cisternal reassembly with that of purified rat liver
p115 (Fig. 3).
Purified RLG were incubated with mitotic cytosol to
generate MGF (Rabouille et al., 1995). Recovery of MGF
(Shorter and Warren, 1999) was followed by incubation
with NSF, 
 
a
 
-, and 
 
g
 
-SNAP and increasing concentrations
of either purified rat liver p115, TA, or the short COOH-
terminal peptides. Cisternal regrowth was monitored by
quantitative EM (Rabouille et al., 1995).
As shown in previous work, p115 stimulated reassem-
bly of cisternae in a concentration-dependent manner
(Shorter and Warren, 1999; Fig. 3). Even without the head
domain TA was almost as efficient, reaching 
 
z
 
70% of the
maximum cisternal reassembly obtained using p115. The
75mer peptide and the 26mer peptide (data not shown)
could not reassemble Golgi cisternae, despite their ability
to bind to GM130 and Giantin (Fig. 2 B). Gel-filtration
(data not shown) and light scattering methods (Table I)
showed that the peptides were monomeric, whereas TA
was dimeric, as is p115 (Waters et al., 1992; Sapperstein et
al., 1995). This suggests the peptides might not function in
the assay because they cannot form dimers.
 
Serine 941 in the Acidic Domain of p115 Is Essential for 
Reassembly of Golgi Cisternae
 
To determine whether phosphorylation of serine 941 was
required for cisternal reassembly we mutated serine 941.
So far it has not been possible to express full-length p115
in 
 
E
 
.
 
 coli
 
. So, since TA was almost as active as full-length
p115, we chose to mutate TA instead. We generated an
 
alanine mutant (TA [S941A]) to prevent phosphorylation
at this site and an aspartic acid mutant (TA [S941D]) since
aspartic acid can mimic a phosphorylated serine residue
(Huang and Erikson, 1994). All three constructs were ex-
pressed in 
 
E
 
.
 
 coli
 
, purified, and characterized so as to
ensure that the mutations had no effect on the physical
or biochemical properties of the protein. Gel filtration
showed that all three had the same molecular weight (data
not shown) and light scattering confirmed that all three
were dimers (Table I). They all had the same sensitivity to
trypsin (data not shown) and they each selectively re-
moved GM130 and Giantin from detergent-solubilized
Golgi extracts (Fig. 4 A). They were all similarly efficient
in linking GM130 to Giantin, as shown below in Fig. 9 B,
GM130 was coimmunoprecipitated with Giantin in a simi-
lar dose-dependent manner for all three of the TA con-
structs.
We then compared the activity of the mutant TAs with
that of TA in cisternal reassembly (Fig. 4 B). TA (S941A)
was unable to support reassembly even at high concentra-
tions, showing that serine 941 is important for its function.
Since the alanine substitution did not significantly alter the
interaction of TA with Giantin and GM130, phosphoryla-
tion of TA appears to be essential for TA function in
Figure 3. The acidic domain
of p115 alone is not sufficient
to stimulate cisternal re-
growth. MGF were incu-
bated with NSF, a-SNAP,
and  g-SNAP and increasing
concentrations of either p115
(squares), TA (ovals), or the
75mer peptide (triangles) for
60 min at 378C. Cisternal re-
growth was measured by
quantitative EM. The results
are presented as the mean of
three experiments 6 SEM.
Table I. Light Scattering Analysis of TA Constructs and the 
75mer Peptide
Mol wt
(calculated)
Mol wt
(measured by light-scattering)
Predicted
oligomerization state
g/mol g/mol
TA 3.80 3 104 (7.42 6 0.06) 3 104 Dimer
TA (S941A) 3.80 3 104 (7.13 6 0.04) 3 104 Dimer
TA (S941D) 3.80 3 104 (7.75 6 0.50) 3 104 Dimer
75mer 8.62 3 103 (8.37 6 2.90) 3 103 Monomer
Light-scattering measurements of TA (2.5 mg/ml), TA (S941A) (1.71 mg/ml), TA
(S941D) (1.6 mg/ml), and the 75mer peptide (1 mg/ml) were carried out using a
miniDAWN machine. Errors represent the standard deviation of the mean molecular
weight.
Figure 4. Cisternal regrowth requires serine 941. (A) Serine 941
in TA was substituted with either alanine (TA [S941A]) or aspar-
tic acid (TA [S941D]) by site-directed mutagenesis. Salt-washed
RLG membranes (200 mg) were extracted in Triton X-100 buffer
and incubated with either Ni-magnetic beads alone or Ni-mag-
netic beads to which an equal amount of TA, TA (S941A) or TA
(S941D) had been coupled. Proteins bound were separated by
SDS-PAGE and visualized by Coomassie staining or Western
blotting using antibodies to Giantin and GM130. (B) MGF were
incubated with NSF, a-SNAP, and g-SNAP and increasing con-
centrations of either TA (ovals), TA (S941A) (triangles) or TA
(S941D) (diamonds) for 60 min at 378C. Cisternal regrowth was
measured by quantitative EM. The results are presented as the
mean of three experiments 6 SEM.The Journal of Cell Biology, Volume 150, 2000 480
Golgi reassembly. TA (S941D) was also unable to stimu-
late reassembly (Fig. 4 B). Hence, it is likely that either the
aspartic acid substitution did not mimic the phosphory-
lated form of TA or that a cycle of phosphorylation/de-
phosphorylation is required for the process by which p115
functions in stimulating membrane fusion.
p115 Forms Containing Serine 941 Can Be 
Phosphorylated by CKII
Having shown that serine 941 is essential for Golgi reas-
sembly it became important to identify the responsible ki-
nase. The kinase would have to be associated with Golgi
membranes, since Golgi reassembly reactions were carried
out in the absence of cytosol. This would also be in agree-
ment with the findings of Ikehara and colleagues who re-
ported that Golgi prepared from HeLa cells contained a
kinase activity capable of phosphorylating Golgi-bound
p115 (Sohda et al., 1998).
We tested whether RLG contained a kinase capable of
phosphorylating purified p115 (Fig. 5 A). p115 was incu-
bated with RLG in the presence of either g-[32P]ATP or
g-[32P]GTP and phosphorylation of p115 monitored. RLG
could phosphorylate p115 in vitro and the responsible ki-
nase was able to use both ATP and GTP as a phosphate
source.
Next, we wanted to know whether p115 was being phos-
phorylated at serine 941. We therefore compared TA and
TA (S941A) as substrates for RLG mediated phosphoryla-
tion and found that only TA was phosphorylated in the
presence of either ATP or GTP (Fig. 5 B). Serine 941 is
clearly the target for the kinase in TA and most likely in the
full-length protein since this serine was the only phosphory-
latable residue in full-length p115 (Sohda et al., 1998).
CKII is the best-characterized kinase known to be able
to use GTP as well as ATP as a phosphate source (Allende
and Allende, 1995). So the fact that RLG-mediated phos-
phorylation of p115 was very efficient in the presence of
GTP indicated that the kinase in question might be CKII
or a CKII-like kinase. Another hint came from the amino
acid sequence surrounding Serine 941, which is very acidic.
CKII is known to phosphorylate serine or threonine resi-
dues flanked by acidic amino acids (Songyang et al., 1996).
Furthermore, CKII has been found associated with mem-
branes (Dittié et al., 1997), although it is mainly a soluble
protein residing predominantly in the nucleus, as well as in
the cytosol (Lorenz et al., 1993).
When RLG was incubated with g-[32P]GTP in the pres-
ence or absence of a CKII peptide substrate, an increase in
protein phosphorylation was observed in the reactions
containing the CKII peptide (Fig. 5 C). Increasing the
amount of RLG used in the reaction increased the amount
of CKII peptide phosphorylation showing that RLG con-
tains CKII or a CKII like activity.
If the RLG kinase, which phosphorylates p115, is indeed
CKII, pure CKII should be able to phosphorylate p115.
p115 was incubated with pure recombinant human CKII
protein (Calbiochem-Novabiochem) in reactions contain-
ing either ATP or GTP. Phosphorylation of p115 took
place using either nucleotide (Fig. 5 D). TA was also a
substrate for recombinant CKII, whereas TA (S941A) was
not (Fig. 5 D). This strongly suggests that CKII phosphor-
ylates p115 at serine 941.
Since MGF were used to reassemble cisternae we
wanted to make sure that they retained the kinase activity
found in the RLG from which they were generated. We
compared the ability of MGF to phosphorylate TA and
TA (S941A) with that of RLG (Fig. 5 E). We found that
MGF did possess the kinase activity that recognized TA,
but not TA (S941A).
Inhibition of CKII Inhibits Golgi Reassembly
Three separate approaches were used to implicate CKII in
the reassembly of Golgi cisternae. We examined the effect
Figure 5. CKII and RLG can phosphorylate serine 941. In vitro
phosphorylation of p115, TA or TA (S941A) was carried out us-
ing RLG, MGF, or recombinant human CKII in the presence of
g-[32P]ATP or g-[32P]GTP. Phosphorylated substrates were visu-
alized after SDS-PAGE and Coomassie staining by exposure to a
PhosphorImager. (A) p115 (0.6 mg) was incubated in the pres-
ence (lanes 1 and 2) or absence (lanes 3 and 4) of RLG for 10 min
at 308C. Reactions contained either g-[32P]ATP (lanes 2 and 4),
or g-[32P]GTP (lanes 1 and 3). (B) 0.2 mg TA (lanes 1 and 2) or
TA (S941A) (lanes 3 and 4) was incubated with RLG in the pres-
ence of either g-[32P]ATP (lanes 1 and 3), or g-[32P]GTP (lanes 2
and 4) for 10 min at 308C. (C) RLG was incubated in the pres-
ence or absence of 10 mg CKII peptide substrate for increasing
time at 308C. Reactions contained 35 mM GTP and g-[32P]GTP.
Phosphorylation activity was quantitated on phosphocellulose fil-
ters by scintillation counting. (D) Recombinant human CKII was
incubated with either 5 mg TA (lanes 1 and 3), TA (S941A)
(lanes 2 and 4), or 0.5 mg p115 (lanes 5 and 6) in the presence of
either g-[32P]GTP (lanes 1, 2, and 5) or g-32P-ATP (lanes 3, 4, and
6). (E) MGF (lanes 1, 2, 5, and 6) or RLG (lanes 3, 4, 7, and 8)
was incubated with 0.2 mg TA (lanes 1, 3, 5, and 7) or TA
(S941A) (lanes 2, 4, 6, and 8) in the presence of g-[32P]GTP
(lanes 1–4) or g-[32P]ATP (lanes 5–8).Dirac-Svejstrup et al. p115 Phosphorylation in Membrane Tethering 481
of adding either drugs known to inhibit CKII, antibodies
to CKII, or CKII peptide substrates.
Four different kinase inhibitors were tested at 100 mM:
staurosporine, 5,6-dichloro-1-b-D-ribofuranosylbenzimida-
zole (DRB), chrysin and roscovitine (Fig. 6 A). Stauro-
sporine has limited selectivity for the kinases it inhibits as
it binds to the catalytic domain of several kinases that
share homology within that region. It is not a potent inhib-
itor of CKII, but does inhibit when added in the mM range
(Meggio et al., 1995). Addition of staurosporine inhibited
cisternal reassembly by about 50%. DRB caused an z50%
reduction of cisternal regrowth. DRB is a relatively spe-
cific inhibitor of CKII, but it may inhibit other kinases
(Shugar, 1994; Yankulov et al., 1995). In contrast, chrysin
is thought to be specific for CKII (Critchfield et al., 1997)
and reduced Golgi reassembly by .75%. Roscovitine,
which was added as a control, is specific for cdc2 and cdk2
(De Azevedo et al., 1997) and showed no significant effect
on cisternal regrowth.
To determine whether the effect of the drugs was re-
lated to phosphorylation of p115 they were added to in
vitro phosphorylation reactions containing RLG and p115
(Fig. 6 B). The same pattern of results was obtained as for
the Golgi reassembly reactions. Addition of staurosporine
resulted in an z70% inhibition of p115 phosphorylation
and DRB inhibited to a similar extent. The most specific
inhibitor, chrysin, reduced phosphorylation by z90%. The
same pattern of inhibition was seen when TA was used as
a substrate for RLG mediated phosphorylation (data not
shown). Several control inhibitors were also tested: rosco-
vitine (Fig. 6 B), KT5720 (a specific inhibitor of protein ki-
nase A), H-89 (an inhibitor of protein kinases A, C and D
and casein kinase I), and calphostin C (inhibitor of protein
kinases C, A, and G). In all cases, at all concentrations
tested, none of these had an effect on RLG mediated
phosphorylation of p115 in the presence of ATP or GTP
(data not shown).
Next, we examined the effect of adding antibodies to
CKII to Golgi reassembly reactions (Fig. 6 C). Antibodies
raised against human CKII-a or -b subunits (Calbiochem-
Novabiochem) both inhibited Golgi reassembly by z45%.
When added to the in vitro phosphorylation assay, these
antibodies inhibited p115 phosphorylation by z50% (Fig.
6 D). Again the effect on Golgi reassembly paralleled the
effect on p115 phosphorylation.
If phosphorylation of p115 by CKII is required for Golgi
reassembly, the addition of CKII peptide substrates should
inhibit by competing with p115 for the kinase. Addition
of the CKII peptide substrate at a 100-fold molar excess
over added p115, resulted in a 70% reduction in cisternal
regrowth (Fig. 6 E). As a control, the same peptide phos-
phorylated on the serine target residue had only a modest
effect (Fig. 6 E).
To ensure that the peptides did not have a general inhib-
itory effect on Golgi reassembly, the effect of the peptides
was examined in the Golgi reassembly pathway that uses
p97 and p47 but does not require p115 for cisternal re-
growth (Shorter and Warren, 1999). Neither the phosphor-
Figure 6. CKII inhibitors inhibit cister-
nal regrowth from MGF and phosphor-
ylation of p115 by RLG. (A, C, and E)
10 mg MGF were incubated with NSF,
a-SNAP, g-SNAP, and maximum con-
centrations of p115 (261 nM). After in-
cubation for 60 min at 378C cisternal
regrowth was measured by quantitative
EM. (B, D, and F) 10 mg RLG was in-
cubated with 0.6 mg p115 for 10 min at
308C in the presence of g-[32P]GTP.
Phosphorylation of p115 was moni-
tored by SDS-PAGE and Coomassie
staining followed by exposure to a
PhosphorImager. (A and B) 100 mM
staurosporine, DRB, chrysin, or rosco-
vitine were present during the incuba-
tion. (C and D) MGF or RLG were
pretreated with antibody directed
against either the a or the b subunit of
human CKII. (E and F) A CKII pep-
tide substrate or the same substrate
phosphorylated on the serine was
present during incubations at a 100-
fold molar excess over added p115. For
all experiments, quantitations repre-
sent the means of two experiments, ex-
cept where error bars are shown and
values represent the means of three ex-
periments 6 SEM.The Journal of Cell Biology, Volume 150, 2000 482
ylated nor the nonphosphorylated forms of the CKII pep-
tide had any effect (data not shown). The inhibition was
therefore specific for the NSF catalyzed Golgi reassembly
pathway, which uses p115.
The effect of adding the peptides to the in vitro phos-
phorylation reactions was examined next (Fig. 6 F). As in
the Golgi reassembly reactions only the nonphosphory-
lated CKII peptide substrate had a significant inhibitory
effect on phosphorylation of p115 by RLG.
We conclude from these data that p115 dependent reas-
sembly of Golgi cisternae requires the activity of CKII or a
CKII like enzyme. Furthermore, it is likely that the re-
quirement is due to its ability to phosphorylate p115, al-
though we cannot exclude the possibility that other CKII
targets are also involved in p115 mediated Golgi reassembly.
Phosphorylation of Serine 941 Enhances Binding to 
Giantin and GM130
Having established a role for serine 941 in the reassembly
of Golgi cisternae, we then wanted to determine how
phosphorylation of this residue affected the function of
p115. The effect of phosphorylating the equivalent of
serine 941 in the 75mer and 26mer peptides on binding to
their Golgi binding partners, GM130 and Giantin, was
therefore tested (Fig. 7).
The phosphorylated and nonphosphorylated 26mers
were coupled to beads and incubated with RLG extracted
in Triton X-100 buffer (Fig. 7 A). The membranes had
been washed with 1 M KCl before extraction to remove
any endogenous p115 that might have interfered with
binding. Phosphorylation of the nonphosphorylated pep-
tide was prevented by omitting ATP and GTP and also by
the salt wash, which removed endogenous CKII activity
(data not shown). As shown in Fig. 7A the phosphorylated
form of the 26mer peptide was at least twice as efficient in
binding Giantin and five times as efficient in binding
GM130 than the nonphosphorylated form.
The binding was also tested in free solution by mixing
the 26mer peptide with extracts of RLG. Again the RLG
was washed with salt before extraction and ATP and GTP
were both omitted from the reaction. The complexes that
formed were then isolated on neutravidin beads using the
biotin tag on the peptide. Since the components were
more dilute, the amounts of complex formed were smaller.
The difference in binding of GM130 and Giantin to the
phosphorylated versus the nonphosphorylated 26mer was
less striking under these conditions, but the phosphor-
ylated peptide did bind more of both proteins (Fig. 7
B). The longer 75mer peptide was also tested and the re-
sults showed a strong effect of phosphorylation of serine
941. The phosphorylated 75mer bound z10 times more
GM130 and Giantin than its nonphosphorylated counter-
part (Fig. 7 B).
p115 Links GM130 to Giantin
Since phosphorylation of serine 941 increased the binding
of p115 peptides to GM130 and Giantin it suggested that
phosphorylation might enhance the function of p115 as a
tethering protein. p115 tethers COPI vesicles to Golgi
membranes and binds to Giantin on the vesicles and
GM130 on the membranes (Sönnichsen et al., 1998). We
suggested that p115 acts as a bridge, linking Giantin to
GM130 and hence the vesicle to the membrane. There
was, however, no direct evidence that such a tethering
complex existed.
Therefore, we set up a system to show that p115 can link
GM130 to Giantin. By carbonate washing of RLG we gen-
erated a Giantin enriched fraction that had ,2% of the
original levels of both p115 and GM130. This was solubi-
lized in Triton X-100 buffer. GM130 was generated by
transcription and translation in vitro and labeled with 35S-
methionine. Solubilized Giantin and 35S-GM130 were then
mixed in the presence of increasing concentrations of
p115. Giantin was immunoprecipitated and the recovery
of GM130 monitored. As shown in Fig. 8 A, GM130 coim-
munoprecipitated with Giantin only in the presence of
p115, the amount increasing linearly with increasing con-
centrations of p115. Formation of the complex depended
on the presence of the NH2 terminus of GM130, contain-
ing the p115 binding site (Nakamura et al., 1997). Mutant
GM130 lacking this NH2 terminus did not coimmuno-
precipitate with Giantin (Fig. 8 C), neither did full-length
GM130 in the presence of an NH2-terminal GM130 pep-
tide (Fig. 8 B) representing the p115 binding site (Naka-
mura et al., 1997). The interaction of p115 with Giantin was
not affected by the presence of the competing GM130 pep-
tide or by the presence of the truncated GM130. Together
these data show that p115 can link GM130 to Giantin.
Similar experiments were also carried out using the TA
construct. As shown in Fig. 8 D, TA was able to link
GM130 to Giantin and did so with a similar efficiency to
p115 (see Fig. 8, A and D).
Linking of Giantin to GM130 by p115 was also shown by
another means (Fig. 8 E). GM130 peptide beads were gen-
erated by coupling the biotinylated peptide representing
the p115 binding site in GM130 to neutravidin beads.
GM130 peptide or mock beads were then incubated in the
presence or absence of excess p115. The beads were subse-
quently washed to remove free p115 and an excess of the
Giantin enriched Golgi fraction added. Mock beads bound
neither p115 nor Giantin. GM130 peptide beads with pre-
Figure 7. Phosphorylation of serine 941 enhances binding to
GM130 and Giantin. (A) Triton X-100 extracts of salt washed
RLG (200 mg) were incubated with either mock beads (lane 1),
26mer beads (lane 2) or beads bound to the 26mer phosphory-
lated at the equivalent of serine 941 (lane 3; 100 mg peptide).
Bound GM130 and Giantin were separated by SDS-PAGE and
visualized by Western blotting. (B) Triton X-100 extracts of salt
washed RLG (40 mg) were incubated alone (lane 1) or with 4 mg
of either the 26mer peptide (lane 2), the 75mer peptide (lane 4)
or their phosphorylated counterparts (lane 3 and 5). The peptides
were recovered on neutravidin beads and bound Giantin and
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bound p115 pulled down Giantin, whereas GM130 peptide
beads with no p115 did not (Fig. 8 E). The binding of Gi-
antin did not displace any p115 (data not shown) showing
that Giantin only bound GM130 through its binding to
p115. These data argue that p115 can link Giantin to
GM130 by interacting with its binding site on GM130
while simultaneously interacting with Giantin. p115 can,
therefore, act as a bridging molecule.
Phosphorylation of Serine 941 Enhances p115-mediated 
Tethering of GM130 to Giantin
We next tested whether the p115 peptides that were able to
bind to GM130 and Giantin could also link them (Fig. 9 A).
Since the data in Fig. 8 showed that Giantin and GM130 do
not interact in the absence of p115, we simplified the assay
by using salt-washed Golgi membranes as the source of
both proteins. Salt washing removes .95% of the endoge-
nous p115, and that remaining (#3 nM final concentration
in the assay) was well below the levels of added p115 and
other constructs. Coimmunoprecipitation of GM130 with
Giantin was monitored by Western blotting. The percent-
age of GM130 brought down was lower than that seen in
the previous assay because chemical rather than radiochem-
ical amounts were being precipitated.
Using this system the TA construct of p115 was again
similar to p115 in its ability to link GM130 to Giantin (Fig.
9 A). Higher levels of TA could be added because it is a
recombinant protein available in larger amounts than
p115. In marked contrast, the 26mer (data not shown) and
75mer (Fig. 9 A) were unable to link GM130 to Giantin
even though they could bind to both proteins (Figs. 2 and
7). The same was true for the phosphorylated peptides
(data not shown). This supports the earlier suggestion that
dimers are needed for tethering.
To test the role of CKII-mediated phosphorylation in
tethering we carried out the assay in the presence or ab-
sence of added recombinant CKII (Fig. 9 B). The TA con-
structs were used so as to exploit mutations at serine 941.
Incubation of the reaction mix with CKII resulted in phos-
phorylation of TA and enhanced the ability of TA to link
Giantin and GM130, the effect being most striking at low
concentrations of TA. At higher concentrations mass ac-
tion overcame the stimulation by phosphorylation. The
tethering complex formed in the presence of TA (S941A)
was not improved by the addition of CKII, showing that
phosphorylation of serine 941 is solely responsible for the
increased efficiency of linking in the presence of CKII. TA
(S941D) did not show elevated linking as compared with
TA (S941A) suggesting that it does not mimic the phos-
phorylated form of p115.
Together, these data argue that p115 acts as a link be-
tween Giantin and GM130 and that this link can be
strengthened by phosphorylation of p115 mediated by
CKII or a CKII-like enzyme.
Discussion
Using a cell-free assay that mimics Golgi reassembly, we
have identified a role for phosphorylation in the vesicle
docking reactions that lead to membrane fusion. The tar-
get is the vesicle tethering protein, p115, and the kinase is
either CKII or a closely related enzyme. Phosphorylation
strengthens the bridge formed by p115 as it links GM130
and Giantin and may work to transfer a tethered vesicle to
the next step of the docking reaction.
p115 Links GM130 to Giantin
The region of GM130 required for p115 binding had previ-
ously been mapped to the first 73 NH2-terminal amino ac-
ids (Nakamura et al., 1997). The Giantin domain required
for p115 binding has also been mapped to the NH2 termi-
nus though it varies from 70 to 448 amino acids, depending
on the laboratory (Linstedt et al., 2000; Lesa et al., 2000).
Research shows that the COOH-terminal tail of p115 is re-
quired for binding to GM130 (Nelson et al., 1998), and,
more recently, for binding to Giantin (Linstedt et al.,
Figure 8. p115 can link
GM130 to Giantin. (A–D)
Carbonate washed RLG mem-
branes (100 mg) were ex-
tracted with Triton X-100
buffer and incubated with in
vitro translated 35S-GM130 in
the absence (A and D) or pres-
ence of an NH2-terminal
GM130 73mer peptide (80 mg;
B), or DN-35S-GM130 (C). Af-
ter incubation in the presence
of increasing concentrations of
p115 (A–C) or TA (D), Gian-
tin was immunoprecipitated
using polyclonal antibodies.
Coimmunoprecipitation of
GM130 or DN-GM130 was
monitored by SDS-PAGE fol-
lowed by PhosphorImager vi-
sualization and quantitation.
Blanks represent background
precipitation of GM130/DN-
GM130 in the absence of Gi-
antin and p115; these were
subtracted during quantita-
tion. Coimmunoprecipitation
of p115 (diamonds) with Gian-
tin was monitored by SDS-
PAGE followed by quantita-
tive Western blotting using
mAbs to p115. (E) Mock beads (lanes 3 and 4) or beads to which
the GM130 peptide had been coupled (lanes 1 and 2) were incu-
bated in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of
excess p115. Free p115 was removed by washing and the beads
were incubated with carbonate washed Golgi extracts (100 mg)
containing Giantin, but no GM130 or p115. Bound p115 and Gi-
antin were visualized by Western blotting.The Journal of Cell Biology, Volume 150, 2000 484
2000). We have confirmed and extended these results,
mapping the binding site to the extreme COOH-terminal
acidic domain. Two peptides covering this region of p115
(a 26mer and a 75mer) both bind to GM130 and Giantin in
RLG detergent extract. They also bind to each protein in
the absence of the other. Hence, in vitro translated
GM130 binds to these peptides but not when the NH2 ter-
minus of GM130 is missing. Carbonate treatment of RLG
removes  .98% of GM130 and p115 leaving Giantin,
which alone can bind to these peptides. Lastly, these pep-
tides will recognize Giantin and GM130 in overlay blots
showing that there is a direct interaction between the
COOH terminus of p115 and both of these proteins.
However, these synthetic peptides were unable to link
GM130 to Giantin, whether they were phosphorylated or
not. Tethering assays showed that GM130 could only be
coprecipitated with Giantin in the presence of p115 or the
TA construct lacking the globular head domain. Dose-
dependent assays showed that the TA construct was z60–
70% as efficient as p115 in linking GM130 to Giantin. The
lack of any linking by the synthetic peptides might reflect
their oligomerization state. Gel-filtration and light scatter-
ing data show that TA, like p115, is dimeric, whereas the
26mer and the 75mer are monomeric. An attractive model
is that dimerization is essential for p115-mediated linking
of GM130 and Giantin, since it would explain how p115
could link GM130 to Giantin when both proteins interact
with the same small region of p115. GM130 and Giantin
would be linked if they each bind to one of the two acidic
domains in the p115 dimer.
This suggestion is inconsistent with recent work from
Linstedt et al. (2000). It showed that p115 and its con-
structs could bind to either GM130 or Giantin but could
not link them. There could be many reasons for the differ-
ence between their results and ours but two points are
worth noting. The first is that none of the reported experi-
ments designed to detect linked complexes of GM130,
p115 and Giantin used full-length GM130 and Giantin.
One or the other of these two proteins was always present
as an NH2-terminal recombinant protein. Though the bind-
ing sites for p115 have been mapped to the NH2 termini of
both proteins, it is possible that other parts of these mole-
cules might be needed to stabilize the tether.
The second reason is that p115 was limiting in those ex-
periments that measured tethering. In the one experiment
we report, where we used the NH2-terminal fragment of
GM130 to bind Giantin, we could only detect bound Gian-
tin when we used excess p115 to saturate the NH2-terminal
fragment (Fig. 8 E). Since stable tethering of vesicles to
membranes is likely the consequence of multiple tethers,
individual tethers might be quite weak so it is important to
keep the concentration of interacting components as high
as possible to observe the tethering complex.
Both the interaction of p115 with GM130 and with Gi-
antin is required in the NSF-catalyzed pathway of mem-
brane fusion (Shorter and Warren, 1999), which involves
p115-mediated tethering of COPI vesicles to Golgi mem-
branes (Sönnichsen et al., 1998). When the interaction
with one p115 binding partner is blocked, the other bind-
ing partner alone is insufficient to allow fusion implicating
both proteins in the same fusion process (Shorter and
Warren, 1999). We therefore favor the idea that p115
functions by interacting with both proteins simultaneously,
acting as a bridge to link GM130 to Giantin.
Truncated forms of p115 only stimulated Golgi reassem-
bly in vitro if they were able to link GM130 to Giantin.
Thus, TA linked GM130 to Giantin and stimulated cister-
nal regrowth with 60–70% of the efficiency observed for
full-length p115. The shorter p115 peptides (whether phos-
phorylated or not) did not stimulate Golgi reassembly and
failed to link GM130 to Giantin. This strongly suggests
that linking of GM130 to Giantin via p115 is a prerequisite
for Golgi reassembly by the NSF pathway and likely rep-
resents the tethering of vesicles before membrane fusion.
Intriguingly, the head domain of p115 was not required for
bridging between GM130 and Giantin, or for stimulating
Golgi reassembly. The head domain has been shown to fa-
cilitate targeting of p115 to the Golgi membrane in vivo
(Nelson et al., 1998). Likewise, association of p115 with
vesicular tubular clusters (VTCs) is also affected by dele-
tions in the head domain, which cause p115 to localize
more with ER-like structures (Nelson et al., 1998). Bind-
ing to these structures does not involve interaction with
GM130 or Giantin (Nakamura et al., 1997; Lesa et al.,
2000). An attractive possibility is that the head domain fa-
cilitates the transport of p115 from VTCs to the Golgi in
vivo, where p115 then performs its function of linking Gi-
antin to GM130 via its acidic domain.
Figure 9. Phosphorylation of serine 941 enhances TA medi-
ated tethering of GM130 to Giantin. (A) Salt washed RLG
membranes (100 mg) were extracted in Triton X-100 buffer and
incubated with increasing concentrations of either p115
(squares), TA (ovals), or the 75mer peptide (triangles). Gian-
tin was immunoprecipitated using polyclonal antibodies and
coimmunoprecipitation of GM130 measured by SDS-PAGE
followed by quantitative Western blotting using a mAb against
GM130. Values represent means of two separate experiments.
(B) Salt washed RLG (100 mg) were solubilized in Triton
X-100 buffer and either TA (squares), TA (S941A) (ovals) or
TA (S941D) (inverted triangles) added at increasing concen-
trations. GTP and g-[32P]GTP was subsequently added to reac-
tions containing TA and TA (S941A) and incubation continued for 10 min at 308C in the presence (crossed symbols) or absence (open
symbols) of recombinant human CKII (0.2 munits; Calbiochem-Novabiochem). Subsequently, immunoprecipitation of Giantin was per-
formed using polyclonal antibodies and coimmunoprecipitation of GM130 measured by SDS-PAGE followed by quantitative Western
blotting using mAbs to GM130. Values represent means of two separate experiments.Dirac-Svejstrup et al. p115 Phosphorylation in Membrane Tethering 485
Phosphorylation of Serine 941 by CKII or
CKII-like Kinase
Mutations in serine 941 prevented cisternal regrowth,
thereby establishing the importance of this residue in the
functioning of p115. Whereas TA could stimulate the re-
growth of MGF into stacked cisternae, TA (S941A) could
not. This suggested that phosphorylation of p115 is re-
quired for its function in Golgi reassembly. However, re-
placing serine 941 with aspartic acid, which can mimic a
phosphorylated serine by introducing negative charge,
also prevented TA function in cisternal reassembly. Yet
since the TA (S941D) did not link GM130 to Giantin bet-
ter that TA or TA (S941A), while phosphorylated TA did
(Fig. 9 B), and the phosphorylated COOH-terminal p115
peptides bound both GM130 and Giantin better than their
nonphosphorylated counterparts (Fig. 7), it seems likely
that the substitution of serine for aspartic acid failed to
mimic the phosphorylated serine.
The Golgi associated kinase that phosphorylates p115 at
serine 941 was identified as CKII or a closely related ki-
nase. CKII is an essential, multi-functional enzyme found
in the nucleus and cytoplasm of all eukaryotic cells (Pad-
manabha et al., 1990; Lorenz et al., 1993; Allende and Al-
lende, 1995). Well over 100 substrates are known (Pinna,
1990) and these include components of the core SNARE
fusion machinery (Nielander et al., 1995; Risinger and
Bennett, 1999). CKII has previously been implicated in
transport events (e.g., Alconada et al., 1996; Cotlin et al.,
1999). However, only its function in recruitment of the
clathrin coat and sorting of Golgi targeted proteins is well
characterized (Mauxion et al., 1996; Dittié et al., 1997;
Wan et al., 1998; Hao et al., 1999).
The identification of CKII as the kinase responsible for
phosphorylating p115 at serine 941 was based of several
observations. First, the sequence surrounding serine 941
resembles a CKII phosphorylation site, comprising EDE-
LESGDQDDE. It does lack the canonical acidic residue
at position 13 but other CKII substrates are known to
lack this residue as well (e.g., Korner et al., 1994). Second,
RLG was found to phosphorylate a generic CKII sub-
strate. Third, RLG phosphorylated p115 and both MGF
and RLG specifically phosphorylated TA at serine 941. In
so doing it could use GTP as well as ATP as the phosphate
source, a hallmark of CKII (Allende and Allende, 1995).
Fourth, recombinant human CKII could phosphorylate
p115 and specifically phosphorylated TA at serine 941.
Fifth, inhibition of CKII by several different types of in-
hibitor prevented phosphorylation of p115 by RLG as well
as Golgi reassembly by the NSF (but not the p97) path-
way. Drugs, most notably the CKII-specific inhibitor,
chrysin, inhibited cisternal regrowth by .75% and p115
phosphorylation by 90%. Antibodies specific for CKII in-
hibited both reactions by 30–50%. Competing CKII sub-
strates also inhibited both assays. In every case, the effect
of CKII inhibitors on Golgi reassembly was paralleled by a
similar inhibitory effect on p115 phosphorylation, suggest-
ing that inhibition of CKII-mediated p115 phosphoryla-
tion is responsible for the effect on Golgi reassembly.
Since we were unable to obtain biochemical amounts of
full-length p115 mutated at serine 941, we could not be
certain that this was the only site acted upon by CKII. It
does, however, appear very likely since Sohda et al. (1998)
showed that serine 941 (942 in the human sequence) is the
only site that is phosphorylated on p115 in vivo. Our find-
ings, therefore, provide very strong support for the idea
that CKII or a very closely related kinase modulates p115
function by phosphorylating serine 941.
Modulation of Bridging by CKII
Two biochemical approaches gave insight into how phos-
phorylation might affect p115 function. First, phosphoryla-
tion of serine 941 resulted in an enhanced affinity for
GM130 and Giantin. COOH-terminal peptides (26mers or
75mers) phosphorylated at serine 941 bound more GM130
and Giantin than their nonphosphorylated counterparts,
both in solution and when immobilized on beads. The in-
crease in binding ranged from 2- to 10-fold (Fig. 7). Sec-
ond, CKII-mediated phosphorylation of TA increased the
efficiency with which complexes between GM130 and Gi-
antin were formed (Fig. 9 B). Importantly, TA (S941A)
mediated linking of GM130 to Giantin was insensitive to
the addition of CKII, showing that serine 941 was the tar-
get for phosphorylation.
Even without phosphorylation, TA and the TA mutants
could still bind GM130 and Giantin (Fig. 4 A) and link
GM130 to Giantin (Fig. 9 B) yet the TA mutants could not
support cisternal regrowth (Fig. 4 B). This suggests that
TA needs to do more than link GM130 to Giantin to re-
build cisternae and that phosphorylation plays a role in
this additional function. One possibility is that it mediates
the transition from vesicle tethering to trans-SNARE pair-
ing perhaps by rearranging the tethers to bring the vesicle
closer to the membrane. Such a rearrangement could ex-
plain the enhanced linking of GM130 to Giantin by phos-
phorylated p115 in our biochemical assay. Phosphorylated
p115 could even recruit SNAREs to the sites where the
vesicle now meets the membrane. Further work will be re-
quired to test this hypothesis, but it would help explain
why overexpression of all ER to Golgi v-SNAREs can
compensate for mutations in the yeast p115 homologue,
Uso1p (Sapperstein et al., 1996). Uso1p mediates the teth-
ering of COPII vesicles to Golgi membranes before
SNARE pairing and tethering involves the small GTPase,
Ypt1p (Sapperstein et al., 1996; Cao et al., 1998). Uso1p
does not have the equivalent serine but there are two sites
at the very beginning of the acidic domain (serines 1,759
and 1,756) that are potential CKII phosphorylation sites.
It is, therefore, possible that CKII phosphorylation is a
general feature of the tethering cycle.
Whatever the role played by phosphorylation it must act
rapidly since Ikehara and colleagues found very little
phosphorylated p115 on Golgi membranes. Almost all was
found in the cytosol suggesting that phosphorylated p115
is released immediately after it has operated on the tether-
ing complexes. During mitosis, however, there was very
little phosphorylated p115 on either the membranes or in
the cytosol (Sohda et al., 1998). Since mitotic phosphoryla-
tion of GM130 by Cdc2 inhibits the binding of p115 (Lowe
et al., 1998) this suggests that p115 is phosphorylated only
after it has bound to GM130 (and perhaps Giantin). Phos-
phorylation of p115 might alter the tethering complex
making it more stable during the tethering phase, whichThe Journal of Cell Biology, Volume 150, 2000 486
might be rapidly followed by the formation of a fusion
complex, which subsequently displaces phosphorylated
p115 to the cytosol. This of course leaves open the ques-
tion as to whether SNAREs are recruited specifically to
the linked complexes containing phosphorylated p115 and
where, when and by which phosphatase the p115 is de-
phosphorylated. Looking for downstream fusion compo-
nents and identifying the p115 phosphatase is the next im-
portant step in working out the other parts of the tethering
cycle.
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